RANO criteria: Definition, Uses, and Clinical Overview

RANO criteria Introduction (What it is)

RANO criteria are standardized rules used to evaluate how brain and other central nervous system (CNS) tumors respond to treatment.
They help clinicians describe whether a tumor is improving, stable, or worsening based on imaging and the patient’s clinical status.
RANO criteria are most commonly applied in neuro-oncology, especially for gliomas and other primary brain tumors.
They are also used in research studies to make results more comparable across hospitals and trials.

Why RANO criteria used (Purpose / benefits)

Cancer care depends on being able to measure change over time. In the brain, this is challenging because tumor appearance on MRI can change for reasons other than true tumor growth or shrinkage. Treatment effects (such as inflammation, radiation-related changes, or altered blood–brain barrier permeability) can mimic progression or response.

RANO criteria were developed to solve several practical problems:

• Standardization of response assessment: They provide shared definitions for response categories (such as response, stability, or progression) so different clinicians and study sites can speak the same language.
• More complete clinical context: Unlike older approaches that focused mainly on contrast-enhancing tumor size, RANO criteria incorporate factors like neurologic symptoms and corticosteroid use, which can strongly influence imaging appearance and patient function.
• Recognition of treatment-related “look-alikes”: RANO criteria were designed in part to address scenarios such as pseudoprogression (treatment-related changes that resemble tumor growth) and pseudoresponse (apparent shrinkage on imaging that may not reflect true tumor control).
• Better trial comparability: In clinical research, consistent response rules help reduce measurement bias and make outcomes more interpretable across different therapies and institutions.
• Support for clinical decision-making: While not a treatment plan, RANO criteria can help frame discussions about whether current therapy appears to be helping, whether additional evaluation is needed, and how urgently changes should be considered.

RANO criteria do not detect cancer, diagnose cancer, or directly determine prognosis on their own. They are a structured way to interpret follow-up findings in a complex organ system where imaging can be ambiguous.

Indications (When oncology clinicians use it)

Clinicians may use RANO criteria in situations such as:

• Assessing treatment response for primary brain tumors (for example, high-grade or low-grade gliomas)
• Monitoring for tumor progression during or after radiation therapy, chemotherapy, targeted therapy, or other systemic treatments
• Interpreting follow-up MRI scans when new or enlarging enhancement appears after treatment
• Evaluating symptoms alongside imaging when a patient has neurologic changes (for example, new weakness, seizures, or cognitive changes)
• Standardizing response reporting for clinical trials in neuro-oncology
• Communicating response status within multidisciplinary care (neuro-oncology, neurosurgery, radiation oncology, neuroradiology, and supportive care teams)

Contraindications / when it’s NOT ideal

RANO criteria are widely used, but they are not always the best fit or may be limited in certain situations, including:

• Non-CNS cancers without brain involvement: For most cancers outside the CNS, other frameworks (such as RECIST) are typically used for tumor measurement and response reporting.
• Inadequate or inconsistent imaging: Poor image quality, incomplete sequences, or changing MRI techniques over time can make RANO-based comparisons unreliable.
• Very early post-treatment imaging: Soon after surgery or radiation, imaging changes can reflect healing, inflammation, or treatment effect rather than true tumor behavior, complicating interpretation.
• Complex mixed pathology or uncertain diagnosis: When the underlying condition is unclear (for example, infection, demyelinating disease, or radiation necrosis vs tumor), additional diagnostic work-up may be needed beyond response criteria.
• Disease patterns that are difficult to measure: Diffuse, infiltrative, or leptomeningeal patterns can be challenging to quantify using standard lesion measurements and may require specialized assessment approaches.
• Situations where clinical context dominates: If a patient’s neurologic decline is clearly driven by a non-tumor issue (such as medication toxicity, metabolic problems, or stroke), response criteria alone may not be the primary tool guiding next steps.

In practice, teams often combine RANO criteria with neuroradiology expertise, clinical exam findings, and—when needed—additional imaging modalities or pathology review.

How it works (Mechanism / physiology)

RANO criteria are not a drug or procedure, so they do not have a biologic “mechanism of action” in the usual sense. Instead, they define a clinical pathway for interpreting tumor status over time, integrating imaging and patient factors that reflect underlying tumor biology and treatment effects.

At a high level, RANO criteria consider:

• Tumor imaging characteristics
• Many CNS tumors are followed with MRI, including contrast-enhanced sequences that highlight regions where the blood–brain barrier is disrupted.
• Non-enhancing tumor components may be assessed on sequences such as T2/FLAIR, which can reflect tumor infiltration, edema (swelling), treatment effect, or a combination.
• Clinical status
• Neurologic function matters because imaging changes do not always match how a person is doing day to day.
• Worsening symptoms can raise concern for progression, but symptoms can also arise from swelling, seizures, medication effects, or other non-tumor causes.
• Corticosteroid use
• Steroids can reduce brain swelling and sometimes reduce enhancement, which may improve symptoms and alter MRI appearance without necessarily indicating true tumor control.

Rather than focusing only on “size,” RANO criteria aim to categorize the overall situation into clinically meaningful response groups (commonly described as complete response, partial response, stable disease, or progressive disease), recognizing that CNS tumors can behave differently from tumors in other organs.

Because RANO criteria are a framework applied at repeat time points, “onset,” “duration,” and “reversibility” do not apply in the way they would for a treatment. The closest relevant concept is that RANO criteria are re-applied at each follow-up assessment, and the assigned category can change as imaging and clinical findings evolve.

RANO criteria Procedure overview (How it’s applied)

RANO criteria are not a procedure performed on a patient. They are applied by clinicians—often involving neuroradiologists and neuro-oncology teams—when reviewing follow-up data. A general workflow commonly looks like this:

1. Evaluation / exam – Review symptoms, neurologic exam findings, and functional status. – Document medications that can affect imaging or symptoms (especially corticosteroids and anti-seizure medicines).

2. Imaging / biopsy / labs – Obtain follow-up brain imaging, typically MRI with and without contrast when appropriate. – Additional tests (advanced MRI techniques, PET imaging, or biopsy) may be considered in selected cases when standard imaging is ambiguous. Whether these are used varies by clinician and case.

3. Staging (contextual, when relevant) – In many primary brain tumors, the concept of “stage” differs from other cancers. – Clinicians still document disease extent (location, multifocality, spread within the CNS) to contextualize response.

4. Treatment planning (contextual) – The care team reviews whether the current therapy is intended to be curative, life-prolonging, symptom-controlling, or supportive, since goals can affect how imaging changes are interpreted.

5. Intervention / therapy (already underway) – RANO criteria are typically applied during ongoing therapy and after therapy completion, rather than being an intervention themselves.

6. Response assessment – Compare current imaging to prior baseline and follow-up studies using consistent measurement rules. – Integrate imaging findings with clinical status and steroid use. – Assign a response category (for example, response, stable disease, or progression) according to the applicable RANO criteria variant.

7. Follow-up / survivorship – Continue surveillance imaging and clinical monitoring according to the patient’s diagnosis, treatment plan, and institutional practice. – Document trends over time rather than relying on a single scan whenever possible.

Types / variations

“RANO criteria” is an umbrella term that includes multiple versions designed for different tumor types and treatment contexts. Common variations include:

• RANO for high-grade gliomas
• Designed to address limitations of earlier measurement systems by incorporating non-enhancing disease features and clinical factors.
• RANO for low-grade gliomas
• Focuses on disease patterns that may be predominantly non-enhancing and can evolve slowly, making assessment different from more aggressive tumors.
• iRANO
• An adaptation intended for patients receiving immunotherapies, where early inflammatory changes can resemble tumor worsening on imaging.
• RANO-BM
• A framework tailored to brain metastases, where lesion number, size, and systemic disease context can influence interpretation.
• Pediatric-focused approaches (often discussed under RANO-related pediatric frameworks)
• Pediatric CNS tumors can differ biologically and radiographically from adult tumors, and response assessment may be adapted accordingly.

Which variation is used depends on tumor type, patient population, treatment modality, and whether assessment is occurring in routine practice or a clinical trial setting.

Pros and cons

Pros:

• Provides a shared, standardized language for response assessment across clinicians and institutions
• Incorporates clinical status and steroid use, not imaging alone
• Helps address CNS-specific pitfalls such as pseudoprogression and pseudoresponse
• Improves consistency in clinical trials, supporting more interpretable results
• Encourages structured longitudinal comparison rather than one-off impressions
• Supports clearer communication in multidisciplinary care teams

Cons:

• Imaging changes can remain ambiguous even when criteria are applied carefully
• Measurements and interpretation can vary with scanner technique, timing, and reader experience
• Some disease patterns are hard to quantify, especially diffuse or leptomeningeal involvement
• Steroids and treatment effects can still confound interpretation, even when documented
• Criteria may not fully capture quality of life, cognition, or subtle neurologic changes
• Different RANO variations can create confusion if the wrong framework is applied to a specific clinical context

Aftercare & longevity

Because RANO criteria are an assessment framework rather than a therapy, “aftercare” is best understood as what typically follows from repeated response assessments: ongoing monitoring, supportive care, and care-plan adjustments based on the overall clinical picture.

Factors that commonly affect outcomes over time include:

• Cancer type and grade: CNS tumors behave very differently depending on histology and molecular features. Prognosis and response patterns vary by cancer type and stage.
• Tumor biology and location: Tumors in or near critical brain regions may cause symptoms with relatively small changes, and this can influence treatment options and functional outcomes.
• Treatment intensity and tolerance: Surgery, radiation, and systemic therapies each have potential benefits and side effects, and tolerability varies by clinician and case.
• Consistency of follow-up imaging: Regular, comparable imaging studies help reduce uncertainty when applying RANO criteria and identifying meaningful trends.
• Supportive care and rehabilitation access: Symptom control, seizure management, neuro-rehabilitation, nutrition, and psychosocial support can affect daily functioning and overall well-being.
• Comorbidities and overall health: Other medical conditions can influence treatment choices, symptom burden, and recovery trajectories.
• Care coordination: CNS tumor care often involves multiple specialties; clear documentation of response status can support smoother transitions between treatment phases and survivorship care.

In general, response categories are most useful when interpreted over time, alongside symptoms and functional status, rather than as a single definitive statement about the future.

Alternatives / comparisons

RANO criteria are one approach among several ways clinicians evaluate cancer response. Comparisons are typically about measurement frameworks, not competing treatments.

Common alternatives or related approaches include:

• Macdonald criteria
• An older system used for some brain tumors that relied heavily on contrast-enhancing tumor measurements. RANO criteria expanded assessment to better address non-enhancing disease and clinical factors.
• RECIST (Response Evaluation Criteria in Solid Tumors)
• Widely used for many cancers outside the CNS. RECIST is often applied to body lesions and may be used alongside RANO criteria when a patient has both systemic disease and brain involvement.
• Clinical observation and longitudinal assessment
• In some cases, clinicians rely on repeated imaging, symptom tracking, and time to clarify whether a change represents tumor progression or treatment effect.
• Surgery vs radiation vs systemic therapy (treatment choices)
• These are not “alternatives” to RANO criteria; rather, RANO criteria may be used to assess response after any of these treatments. The most appropriate treatment approach varies by cancer type and stage.
• Standard care vs clinical trials
• Clinical trials often require strict, protocol-defined response assessment (frequently using RANO criteria or a specified variant). Standard care may use the same principles but with more individualized interpretation.

No single framework perfectly captures all CNS tumor behaviors. Many teams combine structured criteria with expert neuroradiology review and the patient’s clinical course.

RANO criteria Common questions (FAQ)

Q: Are RANO criteria a test or a treatment?
RANO criteria are not a treatment and not a single test. They are a standardized set of rules clinicians use to interpret imaging and clinical information over time. Their role is to describe tumor response or progression in a consistent way.

Q: Does applying RANO criteria cause pain?
No. The criteria themselves are an interpretation method. Any discomfort would come from the underlying assessment process (for example, an MRI scan), not from RANO criteria.

Q: Do I need anesthesia or sedation for a RANO-based assessment?
RANO criteria do not require anesthesia. If sedation is used, it is related to the imaging procedure (such as MRI) and patient-specific needs like severe anxiety, difficulty lying still, or pediatric imaging protocols. This varies by clinician and case.

Q: What side effects are associated with RANO criteria?
RANO criteria do not create side effects because they are not a medication or procedure. Potential risks come from components of monitoring, such as contrast agents for MRI (which can rarely cause allergic reactions) or additional tests ordered to clarify uncertain findings.

Q: How long does a RANO criteria assessment take?
The “assessment” is typically the clinical visit plus imaging review, and timing depends on scheduling and workflow. In clinical trials, imaging time points are usually set by the study protocol; in routine care, timing varies by cancer type and stage and by clinician practice.

Q: Can RANO criteria tell the difference between true progression and pseudoprogression?
RANO criteria are designed to help address this problem, but they do not eliminate uncertainty. Sometimes the distinction becomes clearer with repeat imaging over time, additional imaging techniques, or tissue sampling when appropriate. Interpretation depends on treatment type, timing, and the overall clinical picture.

Q: How much does it cost to be assessed using RANO criteria?
There is no separate “RANO criteria fee” in most settings because it is a method of interpretation. Costs are generally tied to visits, imaging (such as MRI), and any additional testing that may be needed. Coverage and out-of-pocket costs vary by health system and insurance plan.

Q: Will RANO criteria results affect whether I can work or drive?
RANO criteria themselves do not determine activity limits. Work, driving, and other activities are usually guided by symptoms (for example, seizures, weakness, vision changes), treatment side effects, and local safety regulations. Patients should discuss functional restrictions with their clinical team for individualized guidance.

Q: Do RANO criteria affect fertility or pregnancy?
RANO criteria do not affect fertility. However, the treatments being assessed (such as radiation or systemic therapy) may have fertility or pregnancy implications, depending on the regimen and patient factors. These considerations are typically addressed during treatment planning and follow-up.

Q: If my scan is labeled “progression,” does that always mean treatment failed?
Not necessarily. Imaging changes can reflect tumor growth, treatment-related effects, or other processes, and the meaning can depend on timing and therapy type. Clinicians usually interpret the category alongside symptoms, steroid use, and trends across multiple scans before making major care decisions.